Global Dyslipidemia Drugs Market Size, Share, Growth, Trends, Company Analysis and Forecast 2019-2026

Dyslipidemia is a chronic metabolic syndrome, characterized by improper level of low density lipoprotein, high density lipoprotein, and triglycerides. This study on the dyslipidemia drugs market involves the analysis of a wide range of therapeutics that help patients to treat lipid disorders. The dyslipidemia drugs market promises lucrative growth opportunities for pharmaceutical manufacturers due to increasing demand and prescriptions of these medications. According to the Centers for Disease Control and Prevention, cholesterol abnormalities are rapidly increasing in developed regions such as North America and Europe. Moreover, several articles published in open journals stated that demand for lipid lowering drugs is increasing in countries such as China, India, and Japan. However, loss of patent exclusivity of molecules such as Crestor, Zetia, and Vytorin is expected to hamper the growth of the market during the forecast period.

Statins accounted for the largest drugs segment in 2014 and is expected to dominate the market during the study period. The growth of this market is majorly attributed to the availability or high sale of blockbuster drugs such as Lipitor and Crestor. Moreover, bile acid resins recorded around 2.9% share of total dyslipidemia drugs market in 2014 and is expected to lose the market share during the forecast period 2019 - 2026 due to the fact that this drug class offers low efficacy as compared to other commercially available dyslipidemia drugs. However, fibric acid drugs and omega-3 fatty acid derivatives will witness the least decline in the market growth. Positive clinical studies coupled with increasing preference of patients to use omega-3 fatty acid derivatives stimulates the growth of the segment.

Geographically, global dyslipidemia drugs market is studied for North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America accounted for the largest market share and is expected to dominate the market during the forecast period from 2019 to 2026. Rising prevalence rate coupled with presence of one or more branded dyslipidemia formulations augments the growth of North America dyslipidemia market. However, European regions are witnessing the highest growth rate compared to other regions owing to increasing health care awareness about the treatment and management of dyslipidemia.

The market overview section of the report discusses the market dynamics with respect to the market drivers, restraints, and opportunities. This section also covers information on epidemiology, etiology, dyslipidemia diagnostics, trends and future aspects, and market attractiveness analysis, by geography of the dyslipidemia drugs market. A list of recommendations for existing and new players to enter the market and enhance their position is also provided in the report. The report concludes with company profiles of key players operating in various drug classes of the market. Each company profile includes business overview, financial overview, product portfolio, business strategies, and recent developments of the respective market player.

The major players of dyslipidemia drugs market include Pfizer, Inc., AstraZeneca plc, Amgen, Inc., Bayer AG, Merck & Co., Inc., Mylan N.V., Novartis AG, Takeda Pharmaceutical Company Limited and others. These players are investing very huge amount in research and development activities to develop high efficacy dyslipidemia drugs, aiming to enhance their market share in the global dyslipidemia drugs market. For example, Sanofi, in collaboration with Regeneron Pharmaceuticals, Inc. was actively engaged in developing new dyslipidemia drug class molecule Praluent, PCSK9 inhibitor. In July 2015, U.S. Food and Drug Administration (US FDA) approved Sanofi's PCSK9 inhibitor, Praluent, indicated for the treatment of hypercholesterolemia.

The global dyslipidemia drugs market is segmented as follows:

Global Dyslipidemia Drugs Market, by Drug Class

  • Statins
  • Bile Acid Resins
  • Fibric acid and Omega-3 Fatty acid Derivatives
  • Niacins
  • Others (Combination Drugs and Cholesterol Absorption Inhibitors)

Global Dyslipidemia Drugs Market, by Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers